Study With Phage for CF Subjects With Pseudomonas Lung Infection
Public ClinicalTrials.gov record NCT06998043. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Study identification
- NCT ID
- NCT06998043
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2025
- Primary completion
- Feb 28, 2026
- Completion
- Aug 31, 2026
- Last update posted
- Jul 21, 2025
2025 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| Providence Alaska Medical Center | Anchorage | Alaska | 99508 | Not yet recruiting |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | Not yet recruiting |
| Stanford University | Palo Alto | California | 94061 | Not yet recruiting |
| University of California San Francisco | San Francisco | California | 94143 | Recruiting |
| National Jewish Health | Denver | Colorado | 80206 | Recruiting |
| Joe DiMaggio Children's Health | Hollywood | Florida | 33021 | Not yet recruiting |
| Central Florida Pulmonary Group | Orlando | Florida | 32803 | Recruiting |
| Avanza Medical Center | Pensacola | Florida | 32503 | Recruiting |
| Rutgers, Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | Recruiting |
| New York Medical College | Hawthorne | New York | 10593 | Recruiting |
| Northwell Health | New York | New York | 10028 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| University of Utah | Salt Lake City | Utah | 84132 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06998043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06998043 live on ClinicalTrials.gov.